Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cidara Thera (CDTX)

Cidara Thera (CDTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,096
  • Shares Outstanding, K 66,686
  • Annual Sales, $ 12,070 K
  • Annual Income, $ -72,110 K
  • 60-Month Beta 1.07
  • Price/Sales 0.85
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CDTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.07
  • Most Recent Earnings N/A on 11/10/21
  • Next Earnings Date 02/24/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 907.87% ( +479.60%)
  • Historical Volatility 119.86%
  • IV Percentile 99%
  • IV Rank 97.63%
  • IV High 928.26% on 12/27/21
  • IV Low 67.46% on 01/20/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,820
  • Open Int (30-Day) 2,377

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.33
  • Number of Estimates 2
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +32.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7793 +7.42%
on 01/24/22
1.4100 -40.63%
on 01/03/22
-0.4929 (-37.06%)
since 12/23/21
3-Month
0.7793 +7.42%
on 01/24/22
1.7600 -52.44%
on 11/16/21
-0.7029 (-45.64%)
since 10/25/21
52-Week
0.7793 +7.42%
on 01/24/22
3.1500 -73.43%
on 02/16/21
-1.7429 (-67.55%)
since 01/25/21

Most Recent Stories

More News
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics...

CDTX : 0.8371 (+1.32%)
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host...

CDTX : 0.8371 (+1.32%)
Implied Volatility Surging for Cidara Therapeutics (CDTX) Stock Options

Investors need to pay close attention to Cidara Therapeutics (CDTX) stock based on the movements in the options market lately.

CDTX : 0.8371 (+1.32%)
Cidara Therapeutics (CDTX) Reports Q3 Loss, Tops Revenue Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 0.00% and 95.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CDTX : 0.8371 (+1.32%)
Cidara Therapeutics: Q3 Earnings Snapshot

SAN DIEGO (AP) _ Cidara Therapeutics Inc. (CDTX) on Wednesday reported a loss of $18.1 million in its third quarter.

CDTX : 0.8371 (+1.32%)
Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics...

CDTX : 0.8371 (+1.32%)
Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics...

CDTX : 0.8371 (+1.32%)
3 Stocks Under $10 Wall Street Predicts Will Surge by 50%

While there are several concerns, factors such as an expectation of solid third-quarter earnings and the continuation of near-zero interest rate policy should support the stock market in the coming months....

ARCO : 5.88 (+5.00%)
AGRO : 7.55 (+1.07%)
CDTX : 0.8371 (+1.32%)
Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics...

CDTX : 0.8371 (+1.32%)
Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics...

CDTX : 0.8371 (+1.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company...

See More

Key Turning Points

3rd Resistance Point 0.9084
2nd Resistance Point 0.8794
1st Resistance Point 0.8582
Last Price 0.8371
1st Support Level 0.8080
2nd Support Level 0.7790
3rd Support Level 0.7578

See More

52-Week High 3.1500
Fibonacci 61.8% 2.2444
Fibonacci 50% 1.9647
Fibonacci 38.2% 1.6849
Last Price 0.8371
52-Week Low 0.7793

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar